<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799811</url>
  </required_header>
  <id_info>
    <org_study_id>AVG1201.000-M</org_study_id>
    <nct_id>NCT01799811</nct_id>
  </id_info>
  <brief_title>Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization</brief_title>
  <acronym>LIMBSAVE</acronym>
  <official_title>Prospective, Multicenter, Primary Below the Knee Bypass Evaluation With CryoVein® Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CryoLife, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective Study is to evaluate the short- and long-term clinical outcomes of patients&#xD;
      receiving the CryoVein cryopreserved saphenous vein allograft (CVA) as their primary open&#xD;
      bypass conduit to assess if there is a quantifiable correlation to time of placement as a&#xD;
      primary bypass graft and improved long-term clinical outcomes of patients with critical limb&#xD;
      ischemia (CLI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A minimum of 50 CVA will be implanted in enrolled patients at up to 6 participating sites.&#xD;
      The Study will include prospective evaluations on these patients at discharge, 1, 3, 6, 9,&#xD;
      12, 18 and 24 months following surgery. The window for follow-up visits is ± 2 weeks for each&#xD;
      time point. All Study patients will be expected to participate in all follow-up evaluations&#xD;
      unless precluded by patient death.&#xD;
&#xD;
      Patient status and graft performance data will be collected on all patients consented and&#xD;
      enrolled into the Study. The primary endpoint of the Study will be limb salvage. The&#xD;
      secondary endpoints of the Study will include primary patency, secondary patency, morbidity&#xD;
      and mortality per the same reporting standards.&#xD;
&#xD;
      Patient attributes (age, gender, etc.) and preoperative assessments (indication for surgery,&#xD;
      medical history) will be summarized using descriptive statistics. Graft performance will be&#xD;
      presented as freedom from an event endpoint (patient death, graft complication, amputation,&#xD;
      graft explant) as calculated by the Kaplan-Meier method. Log Rank and Cox Regression will be&#xD;
      utilized for comparison between subgroups of the patient population. Statistical software&#xD;
      will be used to compile and analyze all submitted clinical data.&#xD;
&#xD;
      The method of data reporting may include, but is not limited to, a description of the sample&#xD;
      population, frequency distributions of patient demographics, allograft statistics, and&#xD;
      follow-up percentages, summary of event data, correlation analysis, and actuarial analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Limb Salvage</measure>
    <time_frame>Assessed for 24 months following surgery.</time_frame>
    <description>Patients will undergo follow-up assessment for limb salvage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patency</measure>
    <time_frame>Assessed until graft failure over a period of 24 months. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months&quot;.</time_frame>
    <description>Patients with functional grafts will undergo follow-up Study evaluation via Duplex Ultrasound.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>All cause morbidity and mortality</measure>
    <time_frame>Assessed for 24 months following implant surgery.</time_frame>
    <description>Data will be collected on any graft complications such as, but not limited to occlusion, bleeding complications, infection, or aneurysm. Patient survival will also be recorded.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>CLI patient's needing open bypass</arm_group_label>
    <description>Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During the Study follow-up period, a patient may present with an event requiring an open&#xD;
      surgical revision, surgical explant or limb amputation on the (allograft) recipient limb. At&#xD;
      the time of related planned intervention a tissue sample of the affected area of the&#xD;
      allograft may be obtained and, if so, will placed into 10% buffered formalin solution and&#xD;
      returned to CryoLife for histologic analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open&#xD;
        peripheral arterial revascularization.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is an acceptable candidate to receive primary open bypass on the limb&#xD;
             receiving the CVA.&#xD;
&#xD;
          -  CLI diagnosis of Rutherford Class 5 or 6.&#xD;
&#xD;
          -  Tibio-peroneal trunk, Tibial or Peroneal outflow artery.&#xD;
&#xD;
          -  Minimum of 1 patent run-off artery.&#xD;
&#xD;
          -  Serum Creatinine &lt; 2.4 mg/dl.&#xD;
&#xD;
          -  Life expectancy &gt; 2 years from consent.&#xD;
&#xD;
          -  18 years of age or older at the time of consent.&#xD;
&#xD;
          -  Male or non-pregnant female.&#xD;
&#xD;
          -  Ability to understand and provide written informed consent.&#xD;
&#xD;
          -  Willing and able to attend and cooperate with the follow-up examinations.&#xD;
&#xD;
          -  Able to follow Study required post-operative daily aspirin and/or other oral&#xD;
             anticoagulation/antiplatelet regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient currently receiving hemodialysis for end stage renal disease.&#xD;
&#xD;
          -  Known hypercoaguable state.&#xD;
&#xD;
          -  Known heparin allergy.&#xD;
&#xD;
          -  Patients with any condition which, in the opinion of the investigator could preclude&#xD;
             evaluation of response or completion of follow-up or affect patient safety.&#xD;
&#xD;
          -  Currently being treated with an investigational device or drug (within 3 months prior&#xD;
             to surgery).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Capps, MS</last_name>
    <role>Study Director</role>
    <affiliation>CryoLife, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Heart Institue</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Walker PJ, Mitchell RS, McFadden PM, James DR, Mehigan JT. Early experience with cryopreserved saphenous vein allografts as a conduit for complex limb-salvage procedures. J Vasc Surg. 1993 Oct;18(4):561-8; discussion 568-9.</citation>
    <PMID>8411463</PMID>
  </reference>
  <reference>
    <citation>Shah RM, Faggioli GL, Mangione S, Harris LM, Kane J, Taheri SA, Ricotta JJ. Early results with cryopreserved saphenous vein allografts for infrainguinal bypass. J Vasc Surg. 1993 Dec;18(6):965-9; discussion 969-71. Review.</citation>
    <PMID>8264053</PMID>
  </reference>
  <reference>
    <citation>Lesèche G, Penna C, Bouttier S, Joubert S, Andréassian B. Femorodistal bypass using cryopreserved venous allografts for limb salvage. Ann Vasc Surg. 1997 May;11(3):230-6.</citation>
    <PMID>9140596</PMID>
  </reference>
  <reference>
    <citation>Martin RS 3rd, Edwards WH, Mulherin JL Jr, Edwards WH Jr, Jenkins JM, Hoff SJ. Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization. Ann Surg. 1994 Jun;219(6):664-70; discussion 670-2.</citation>
    <PMID>8203975</PMID>
  </reference>
  <reference>
    <citation>Farber A, Major K, Wagner WH, Cohen JL, Cossman DV, Lauterbach SR, Levin PM. Cryopreserved saphenous vein allografts in infrainguinal revascularization: analysis of 240 grafts. J Vasc Surg. 2003 Jul;38(1):15-21.</citation>
    <PMID>12844083</PMID>
  </reference>
  <reference>
    <citation>Bannazadeh M, Sarac TP, Bena J, Srivastava S, Ouriel K, Clair D. Reoperative lower extremity revascularization with cadaver vein for limb salvage. Ann Vasc Surg. 2009 Jan-Feb;23(1):24-31. doi: 10.1016/j.avsg.2008.04.011. Epub 2008 Jul 26.</citation>
    <PMID>18657383</PMID>
  </reference>
  <reference>
    <citation>Buckley CJ, Abernathy S, Lee SD, Arko FR, Patterson DE, Manning LG. Suggested treatment protocol for improving patency of femoral-infrapopliteal cryopreserved saphenous vein allografts. J Vasc Surg. 2000 Oct;32(4):731-8.</citation>
    <PMID>11013037</PMID>
  </reference>
  <reference>
    <citation>Zehr BP, Niblick CJ, Downey H, Ladowski JS. Limb salvage with CryoVein cadaver saphenous vein allografts used for peripheral arterial bypass: role of blood compatibility. Ann Vasc Surg. 2011 Feb;25(2):177-81. doi: 10.1016/j.avsg.2010.07.020.</citation>
    <PMID>20889296</PMID>
  </reference>
  <reference>
    <citation>Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010 Apr;51(4):869-77. doi: 10.1016/j.jvs.2009.11.062.</citation>
    <PMID>20347683</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allograft</keyword>
  <keyword>limb salvage</keyword>
  <keyword>patency</keyword>
  <keyword>Cryopreserved</keyword>
  <keyword>open bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Post market study of 361 product; not supporting any FDA approvals.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

